To L B
Leukaemia Research Unit, Hanson Centre for Cancer Research, Adelaide, Australia.
Stem Cells. 1993 Jul;11(4):283-9. doi: 10.1002/stem.5530110405.
Autologous hemopoietic stem cell rescue following high-dose chemoradiotherapy is increasingly used in the treatment of lymphohemopoietic malignancy and selected solid tumors. While encouraging disease control has been reported in acute leukemia, lymphoma, multiple myeloma and breast carcinoma, such an approach suffers from a number of limitations. This review addresses a number of issues that may lead to better stem cells for transplant: which stem cell rescue provides the most rapid hemopoietic reconstitution, how can we get sufficient high quality stem cells for transplant to ensure complete and sustained reconstitution, what are the predictors of rapid and sustained hemopoietic reconstitution, what impact on hemopoietic reconstitution purging and positive selection technology may have, and how can we abrogate the obligatory delay to blood count recovery.
大剂量放化疗后自体造血干细胞救援越来越多地用于治疗淋巴造血系统恶性肿瘤和某些实体瘤。虽然在急性白血病、淋巴瘤、多发性骨髓瘤和乳腺癌中已有令人鼓舞的疾病控制报告，但这种方法存在一些局限性。本综述探讨了一些可能有助于获得更好的移植干细胞的问题：哪种干细胞救援能实现最快的造血重建，我们如何获得足够数量的高质量移植干细胞以确保完全和持续的重建，快速和持续造血重建的预测因素是什么，净化和阳性选择技术对造血重建可能有什么影响，以及我们如何消除血细胞计数恢复的必然延迟。
